Actions that aim to: facilitate drug development of treatments that are curative or disease modifying for dementia; or ensuring that drugs and treatments are more affordable and accessible to patients worldwide. Including but not limited to:
- Reducing the barriers to timely dementia drug development.
- Making drugs and treatments more accessible to dementia patients.
- Encouraging innovation and collaboration between different sectors such as government, industry, regulators and the scientific community.
|Country / Organisation||Pledge|
|Canada||Participation in the Integrated Development project is being undertaken by Health Canada.|
|Cuba||A National Strategic Plan to implement Good Clinical Practice Guidelines for prevention and management of chronic diseases, with a community out-reach component, trials of multi-dimensional assessment, risk stratification and intervention in primary care.|
|Dominican Republic||The Dominican Republic fully endorses and supports the search for a cure or disease modifying treatment.|
|Greece||As part of the national dementia action plan in Greece, there are aims to improve (early) diagnosis and treatment.|
|Indonesia||Early detection of, diagnosis of, and holistic procedures for cognitive and Dementia-related problems.|
|Japan||Japan will aim to create a domestic registry system for persons with dementia, considering possible collaboration with global partners which intend to establish the same registry.|
|United Kingdom|| Integrated Development
To consider what scientific and regulatory approach is now needed to facilitate disease-modifying drug development and registration in a global environment; and examine what scientific and regulatory tools we have at our disposal today and can use, with regard to the different disease stages in Alzheimer’s and other dementing illnesses.
The Dementia Discovery Fund will take a ground-breaking approach to financing dementia research through joint investment of major pharmaceutical companies, UK government and a leading research charity. The Fund aims to harness the talent of world leading scientists to expand early dementia research and supports the ambition to find a cure or disease modifying treatment by 2025, which is a 2013 G8 commitment. This is the first step in a significant journey to developing the Fund, organisations involved recognise that joining together and sharing knowledge and expertise will increase the chances of creating the therapies needed to improve the lives of people affected by dementia.
|Alzheimer’s Association||Identify knowledge gaps and funding opportunities to accelerate the advancement of therapeutic drug development for disease-modifying treatments.
Facilitate collaborative forums to identify opportunities to reduce timeline for drug development
|The European Commission||The Innovative Medicines Initiative (IMI) is Europe’s largest public-private initiative aiming to speed up the development of better and safer medicines for patients. IMI supports collaborative research projects and builds networks of industrial and academic experts in order to boost pharmaceutical innovation in Europe.|
|The Global CEO Initiative on Alzheimer’s Disease||The Global Alzheimer’s Platform
Speed up drug development by developing a Global Alzheimer’s Platform (GAP) to reduce the time, cost, and risk of drug testing, as well as advance the scientific understanding of disease pathogenesis and increase the capacity and efficiency of clinical trials. Our work in 2015 will be to continue to develop regional partners to support the global infrastructure development, including building on the formal relationship we have with Innovative Medicines Initiative’s EPAD, strengthening the early commitment with Canadian Consortia on Neurodegeneration in Ageing and initiating work with newly found partners in Asia.
|Young Leaders|| Innovative Funding
We will help policy makers develop innovative, collaborative funding strategies to strengthen existing and new collaborations across disciplines, sectors, and nations. We will lead a joint effort with governments and NGOs to update our respective regions’ research networks according to funding, research topics, populations, initiatives, practice improvement, and policy developments.